Agamree access in Egypt: the EDA named-patient pathway
How Egypt patients legally obtain Agamree (vamorolone) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Agamree in Egypt
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Agamree (vamorolone) is a dissociative steroid (a corticosteroid with reduced bone, growth, and metabolic side effects) approved by the US FDA in October 2023 for Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. The drug is manufactured by Catalyst Pharmaceuticals (Santhera US partner). Egypt patients use the Egyptian Drug Authority named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, builds the documentation packet your physician needs to file, and orchestrates the logistics into Egypt with a single point of contact carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Agamree reaches patients in Egypt
Agamree (vamorolone, an oral dissociative steroid manufactured by Catalyst Pharmaceuticals under the Santhera development partnership) received US FDA approval in October 2023 for Duchenne muscular dystrophy in patients 2 years of age and older, with the labelled regimen of 6 mg/kg once daily as a 40 mg/mL oral suspension per the FDA label at accessdata.fda.gov. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg shows no public registration record for vamorolone or Agamree as of 2026-06-01. Egyptian patients access the drug under the Personal Importation of Unregistered Medicines pathway administered by the EDA Central Administration for Pharmaceutical Affairs, which sits under Pharmacy Practice Law No. 127 of 1955 read with Health Minister Decree No. 296 of 2009 and the post-2019 EDA framework established by Law No. 151 of 2019 at edaegypt.gov.eg. The application is filed in Cairo at the EDA Central Administration or at a regional EDA office. For Agamree specifically, the treating Egyptian-licensed paediatric neurologist issues a stamped medical report stating the DMD diagnosis with genetic confirmation of a pathogenic DMD gene variant (any mutation type; vamorolone is not exon-restricted), the prior corticosteroid history if any, the weight-based dose and treatment duration, and the clinical rationale referencing the VISION-DMD phase 2b trial (NCT03439670) at clinicaltrials.gov. The EDA does not publish a fixed processing-time SLA; patient-organisation reporting and consultancy summaries (PharmaBoardroom Egypt Legal Handbook at pharmaboardroom.comWe give you a written timeline estimate for your case before you commit. Each shipment requires a fresh permit and convention is up to a three-month supply per application; chronic-therapy DMD patients re-file per cycle. A parallel institutional-import lane allows tertiary hospitals to file on the prescribing physician's behalf.
Where Agamree is dispensed in Egypt
Agamree is an oral paediatric drug given at home by the parent or caregiver with quarterly clinic review of weight, blood pressure, glycaemia, bone health surveillance, and DMD-specific cardiac and pulmonary function testing per standard DMD care. The Egyptian tertiary centres that hold the paediatric neurology and neuromuscular profile relevant to Agamree dispensing include Abu El Reesh Children's Hospitals at Cairo University with paediatric neurology and medical genetics, accessible through the Kasr Al-Ainy hospital network at medicine.cu.edu.eg; the Children's Cancer Hospital Egypt 57357 in Cairo, which while primarily oncology hosts paediatric subspecialty pharmacy operations frequently involved in named-patient imports at 57357.org; Ain Shams University Children's Hospital in Cairo with paediatric neurology; Mansoura University Children's Hospital with its paediatric neuromuscular clinic at muchu.mans.edu.eg; and Alexandria University Children's Hospital (Shatby campus) with paediatric neurology. The Magdi Yacoub Heart Foundation at Aswan at magdiyacoubfoundation.org is the reference centre for DMD-related cardiomyopathy surveillance when patients are referred for cardiac workup. Abu El Reesh and Mansoura are the most frequent dispensing nodes for paediatric named-patient imports because they hold institutional-import experience under the Special Permission framework.
What Agamree costs in Egypt
Medicine price: quote on request. You get a written quote for your case before you commit. Cost layers beyond the drug itself include ambient-temperature international logistics (Agamree is a room-temperature oral suspension and does not require cold chain), the EDA permit and customs duties, the dispensing facility administration fees, and the Reserve Meds coordination fee itemised separately on every firm quote.
Funding and access barriers for Agamree in Egypt
DMD therapy funding in Egypt sits in the long-tail rare-disease category and is not handled uniformly. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg, established under Law No. 2 of 2018, is the statutory payer for insured citizens in implementation governorates and co-administers the Health Technology Assessment process with the Unified Procurement Authority; UHIA rollout remains phased and DMD-modifying therapies have not been publicly added to the UHIA reimbursement list as of 2026-06-01. The Treatment at State Expense scheme (Nafaqat Ala Al-Dawla) administered through MOHP funds case-by-case high-cost treatment for Egyptian nationals lacking means; DMD paediatric cases have used this lane historically for corticosteroid-class drugs and the route is case-decided. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) typically exclude or sub-limit unregistered named-patient imports on retail policies and assess corporate group policies case by case. Out-of-pocket spending has historically dominated Egyptian health financing per World Bank data at data.worldbank.org, and for paediatric rare-disease imports outside UHIA scope the dominant pattern is family self-pay supplemented by Treatment at State Expense applications and charitable hospital pharmacy support. The Egyptian Society of Paediatric Neurology and parent-led DMD support groups are the practical referral networks for families navigating the documentation set.
Recent regulatory and access news for Agamree
The EDA published consolidated guidance on personal-use and institutional imports of unregistered therapeutic goods through the Central Administration for Pharmaceutical Affairs; the current operative reference for an Agamree permit application sits on the EDA news feed at edaegypt.gov.eg/en/news. UHIA and the Unified Procurement Authority have continued the phased rollout of the Universal Health Insurance system across implementation governorates including Port Said, Ismailia, Suez, Aswan, Luxor, and South Sinai per UHIA disclosures at uhia.gov.eg; the payer mix for paediatric specialty drugs differs by governorate. The European Medicines Agency authorised vamorolone in the EU in December 2023 with the European Public Assessment Report published at ema.europa.eu, and the EMA listing is a recognised reference-authority basis the EDA application can cite. No drug-specific EDA bulletin for vamorolone or Agamree over the last 12 months has been observed as of 2026-06-01.
Where Reserve Meds fits in Agamree cases
Reserve Meds is a US-based digital health company. We do not replace your Egyptian specialist, we do not replace the EDA, and we do not replace your dispensing pharmacy. For Agamree specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into Egypt, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your Egyptian physician has prescribed Agamree and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.